

Figure 1 - mean change in HbA1c(%) from baseline by visit – mITT population




LOCF = Last observation carried forward.
Note: The plot included measurements obtained up to 14 days after the last injection of the investigational medicinal product.

Figure 2 - mean change in body weight (kg) from baseline by visit – mITT population




LOCF = Last observation carried forward.
The analysis included measurements obtained up to 3 days after the last injection of the investigational medicinal product.

Figure 3 - mean insulin glargine daily dose (U) by visit – mITT population




LOCF = Last observation carried forward.
The analysis included measurements obtained up to the date of last injection of the investigational medicinal product.
The dose of insulin glargine are collected on 3 different days during the week prior to the visit and the values presented are the average of the collected doses except for Week -12 when the dose was collected only once for the visit.

Figure 4 - mean daily insulin glulisine dose (U) by visit – mITT population



LOCF = Last observation carried forward.
The analysis included measurements obtained up to the date of last injection of the investigational medicinal product.
The insulin glulisine doses were collected on 3 different days during the week prior to the visit and the values presented are the average of the collected doses.

Figure 5 - mean total insulin dose (U) by visit – mITT population



LOCF = Last observation carried forward.
The analysis included measurements obtained up to the date of last injection of the investigational medicinal product.
Total insulin dose is the sum of average insulin glargine dose and average insulin glulisine dose for the visit.




Figure 6 - graphical study design